Floatz logo

Orantinib

Multiple Myeloma and Plasma Cell Neoplasm

Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

498 Active assets in the Multiple Myeloma and Plasma Cell Neoplasm cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

Orantinib is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
56 / 100
View asset →
cancer of unknown primary siteDormant
CC
Indicative ·
46 / 100
View asset →
kidney cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →